Measurement of KIM-1 and VDBP may therefore allow clinicians to identify patients at heightened risk of AKI before serum creatinine rises, enabling early nephroprotective interventions and tailored management strategies. This evidence concerns the gene HAVCR1 and acute kidney injury.